Veracyte (VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SIVB). Veracyte said, "As of December 31, 2022, the company had $178.9 million in cash, cash equivalents and short-term investments. The majority of these assets are not restricted by the Federal Deposit Insurance Corporation’s action to take control of SVB. The company believes its currently accessible cash, cash equivalents and short-term investments will be sufficient to satisfy its operations and obligations."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VCYT:
- Veracyte sees FY23 revenue $325M-$335M, consensus $329.57M
- Veracyte reports Q4 EPS (5c), consensus (15c)
- Biotech Alert: Searches spiking for these stocks today
- Veracyte: Value of test for men with high risk prostate cancer validated
- ‘Stay Long and Strong’: Billionaire Ken Fisher Snaps Up These 2 ‘Strong Buy’ Stocks